CELLTRION
18.5.2021 08:41:05 CEST | Business Wire | Press release
Celltrion Group today announced that CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has confirmed neutralising potency against emerging variants first identified in New York (B.1.526), Nigeria (B.1.525) and India (B.1.617).1
The Korea Disease Control and Prevention Agency (KDCA) has assessed the test by combining the antibody with recent emerging variants first identified in New York (B.1.526), Nigeria (B.1.525) and Brazil (P.1); infecting the host cell with this combination to identify neutralising effect against the variants with CT-P59. The monoclonal antibody candidate CT-P59 demonstrated strong neutralising capability against the New York (B.1.526) and Nigeria (B.1.525) variants and produced neutralising titers against the Indian variant (B.1.617) in an in-vitro pseudo virus assay.1
The company plans to study neutralising titers against additional emerging strains, including the Brazil variant (P.1)2 , in order to proactively address the pandemic as the virus continues to evolve. CT-P59 is known to successfully neutralise the SARS-CoV-2 variants first identified in the UK (B.1.1.7), California (B.1.427/B.1.429), Brazil (P.2), in addition to the previously identified six variant genome mutations of SARS-CoV-2 (variants S·L·V·G·GH·GR).
“The emergence of SARS-CoV-2 variants has created great concern across the globe. We are encouraged by these results, which reinforce our confidence that CT-P59 should be effective against these newly detected variants.” said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare. “Monoclonal antibodies have the potential to alleviate symptoms and prevent progression to severe disease in patients with mild to moderate COVID-19. It’s clear there is an urgent need to improve access to treatments like regdanvimab, as emerging variants continue to threaten efforts to curb the spread of the virus around the world.”
Celltrion has successfully enrolled more than 1,300 people and its global Phase III clinical trial to further evaluate the efficacy and safety of CT-P59 in 13 countries including the U.S., Spain and Romania is on track with data expected in the coming months.
As of May 2021, more than 3,000 people have been treated with regdanvimab in the Republic of Korea.
- ENDS -
Notes to Editors:
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us
.
About regdanvimab (CT-P59)
CT-P59 was identified as a potential treatment for COVID-19 through screening of antibody candidates and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus. In vitro
and in vivo
pre-clinical studies showed that CT-P59 strongly binds to SARS-CoV-2 RBD and significantly neutralise the wild type and mutant variants of concern including the UK variant (B.1.17). In in vivo
models, CT-P59 effectively reduced the viral load of SARS-CoV-2 and inflammation in lung. Results from the global Phase I clinical trial of CT-P59 demonstrated a promising safety, tolerability, antiviral effect and efficacy profile in patients with mild symptoms of COVID-19.1
Celltrion also has recently commenced the development of a neutralising antibody cocktail with CT-P59 against new emerging variants of SARS-CoV-2.
References
1 Celltrion Data on file
2 SARS-CoV-2 variants of concern as of 11 May 2021. European Centre for Disease Prevention and Control. Available from: https://www.ecdc.europa.eu/en/covid-19/variants-concern
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517006051/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Brings Flagship Kinexions Conference to India, Showcasing Growing Market Momentum17.11.2026 02:30:00 CET | Press release
Inaugural event features leaders from Tata Consumer Products and Sun Pharma, highlighting India's growing role in global supply chain innovation Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today opened its first-ever Kinexions India conference in Mumbai, highlighting the company's growing presence in the country and India's importance to its global innovation and customer delivery operations. With teams in Chennai and Bangalore supporting product development, engineering, professional services and customer success, India plays an important role in Kinaxis' global operations. The company continues to invest in research and development in India, strengthening its engineering and innovation capabilities to support the next generation of AI and supply chain orchestration technologies. "India plays an important role in how we innovate and support customers around the world," said Razat Gaurav, CEO of Kinaxis. "Bringing Kinexions here for
Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa16.11.2026 22:30:00 CET | Press release
European Commission approval based on data from Phase 3 STOP-HS1 and STOP-HS2, which showed that Povofortay® (povorcitinib) met the primary endpoint at Week 12 and delivered clinically meaningful, durable responses through Week 54 and was well tolerated 1,2 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Povofortay® (povorcitinib) 45 mg and 75 mg for the treatment of eligible adults with moderate to severe hidradenitis suppurativa (HS). “The European Commission approval of Povofortay marks an important milestone for Incyte, advancing a key growth driver for our business and bringing a new treatment option to people living with HS, a chronic and often debilitating disease,” 2,3 said Bill Meury, Chief Executive Officer, Incyte."As the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, Povofortay gives physicians an important new option for their patients.” The approval is based on res
Moody’s Names Timothy Bhatt as Chief Information Officer16.11.2026 22:00:00 CET | Press release
Bhatt to lead enterprise technology strategy, AI deployment, and cyber and information security in Executive Leadership Team role Moody’s Corporation (NYSE: MCO) announced today that it has named Tim Bhatt to the newly created role of Chief Information Officer (CIO), effective December 7th, and that he will join the company’s Executive Leadership Team. Mr. Bhatt, who has served as Chief Technology Officer (CTO) of Moody’s Ratings since 2018, will also continue in that role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116893391/en/ Timothy Bhatt, Chief Information Officer, Moody's As CIO, Mr. Bhatt will lead Moody’s enterprise technology strategy, AI enablement, and information security, with responsibility for the company’s technology services and operations and cybersecurity teams. He will further modernize how Moody’s operates, bringing together human expertise, trusted data and AI agents to reimagine enterprise work
Lattice Extends Space Heritage with On-Orbit Milestone in TESAT Optical Communication Terminals16.11.2026 22:00:00 CET | Press release
Radiation-resilient Lattice Nexus FPGAs have operated as specified in TESAT optical communication terminals since 2025 Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that its low power, radiation-resilient Lattice Nexus™ FPGAs have surpassed one year of on-orbit operation in TESAT optical communication terminals. Since launch, the FPGAs have delivered consistent performance in the demanding application of space-based laser communication at 10 Gbps, adding to Lattice’s space heritage of thousands of FPGAs launched to date. TESAT has flown optical communication terminals on GEO and LEO missions for more than a decade, supplying broadband constellations and institutional programs. For the redesign of its terminal electronics, Lattice Nexus FPGAs addressed TESAT’s requirements for radiation tolerance, low power, and board footprint. Built on 28 nm fully depleted silicon-on-insulator (FD-SOI) process technology, the Nexus platf
New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 18:00:00 CET | Press release
New Survey of More Than 4,000 Players Finds 78% Play More During the Holidays and 82.5% Would Watch a Rewarded Ad in Exchange for a Bonus Offer Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an aud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
